Johnson & Johnson (JNJ) — insider trading
Health Care · NYSE
Johnson & Johnson (JNJ) has 16 reported SEC Form 4 insider transactions in our data, including 1 open-market sale among the most recent 16 (latest 2026-06-11).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-11 | Wengel Kathryn E | Officer (EVP, Chief TO and Risk Officer) | Option exercise / conversion (derivative) | 10,000 | $0.00 | $0 | Form 4 |
| 2026-06-11 | Wengel Kathryn E | Officer (EVP, Chief TO and Risk Officer) | Open-market sale | 10,000 | $241.15 | $2.41M | Form 4 |
| 2026-06-11 | Wengel Kathryn E | Officer (EVP, Chief TO and Risk Officer) | Option exercise / conversion | 10,000 | $115.67 | $1.16M | Form 4 |
| 2026-06-09 | HEWSON MARILLYN A | Director | Grant / award / vesting (derivative) | 215 | $232.79 | $50.0K | Form 4 |
| 2026-06-09 | Pinto Daniel E | Director | Grant / award / vesting (derivative) | 134 | $232.79 | $31.2K | Form 4 |
| 2026-06-09 | Woods Eugene A. | Director | Grant / award / vesting (derivative) | 161 | $232.79 | $37.5K | Form 4 |
| 2026-05-01 | REED JOHN C | Officer (EVP, Innovative Medicine, R&D) | Option exercise / conversion (derivative) | 25,255 | $0.00 | $0 | Form 4 |
| 2026-05-01 | REED JOHN C | Officer (EVP, Innovative Medicine, R&D) | Shares withheld for taxes / exercise cost | 11,002 | $229.85 | $2.53M | Form 4 |
| 2026-05-01 | REED JOHN C | Officer (EVP, Innovative Medicine, R&D) | Option exercise / conversion | 25,255 | $0.00 | $0 | Form 4 |
| 2026-04-23 | Joly Hubert | Director | Grant / award / vesting (derivative) | 975 | $0.00 | $0 | Form 4 |
| 2026-04-23 | McClellan Mark B. | Director | Grant / award / vesting (derivative) | 975 | $0.00 | $0 | Form 4 |
| 2026-04-23 | MORIKIS JOHN G | Director | Grant / award / vesting (derivative) | 1,540 | $0.00 | $0 | Form 4 |
| 2026-04-23 | Pinto Daniel E | Director | Grant / award / vesting (derivative) | 1,712 | $0.00 | $0 | Form 4 |
| 2026-04-23 | WEINBERGER MARK A | Director | Grant / award / vesting (derivative) | 975 | $0.00 | $0 | Form 4 |
| 2026-04-23 | West Nadja | Director | Grant / award / vesting (derivative) | 975 | $0.00 | $0 | Form 4 |
| 2026-04-23 | Woods Eugene A. | Director | Grant / award / vesting (derivative) | 975 | $0.00 | $0 | Form 4 |
Ask the chat about JNJ's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Johnson & Johnson (JNJ).
Last updated 2026-06-11 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.